Since the FDA relaxed its regulations on how abortion pills reach patients, at least seven women have filed lawsuits claiming someone slipped them the drugs without their knowledge or consent, ending pregnancies they wanted to keep. The cases span multiple states, involve boyfriends and husbands as the alleged perpetrators, and raise a question the regulatory debate has largely sidestepped: what happens when easier access to these pills becomes a weapon?
In 2021, the FDA permanently lifted its longstanding requirement that mifepristone, the first drug in the two-pill abortion regimen, be dispensed in person at a clinic or medical office. The change allowed the drug to be prescribed via telehealth and shipped directly to patients by mail. Supporters called it a victory for access. Critics warned it would make the pills far harder to track and far easier to misuse.
The Daily Caller documented seven civil lawsuits filed by women who say that regulatory loosening enabled exactly the scenario critics feared. In each case, the woman alleges a man obtained abortion drugs and administered them to her covertly, typically by dissolving them in food or a drink.
Every lawsuit was filed after the FDA's 2021 rule change. The plaintiffs' claims center on the argument that removing in-person dispensing safeguards made it trivially easy for someone other than the pregnant woman to acquire the pills online and use them as a tool of coercion.
The lawsuits share a disturbing blueprint. In each, the woman says she told her partner she intended to carry the pregnancy to term. The man allegedly disagreed and, rather than accept her decision, procured abortion pills through mail-order channels and secretly put them in something she consumed. The women describe experiencing sudden, severe bleeding and losing their pregnancies before learning what had been done to them.
The cases were filed in states including Texas, Arkansas, and North Carolina. Some name the man who allegedly administered the drug. Others name the telehealth prescribers or online pharmacies that filled the orders, arguing those entities failed to verify that the person ordering the pills was actually the patient who would take them.
Several of the lawsuits specifically cite the FDA's decision to drop the in-person dispensing requirement as a but-for cause of the harm. The legal theory: had the old safeguards remained in place, the men could not have obtained the drugs so easily and anonymously.
The civil suits are not the only legal fallout. In one of the most serious cases to emerge from this pattern, a Department of Justice IT worker in Texas faces capital murder charges after allegedly slipping an abortion drug into his pregnant girlfriend's drink. Justin Banta, 38, was arrested in Parker County and charged with capital murder and tampering with physical evidence, Fox News reported.
Police said the victim was approximately six weeks pregnant and had a sonogram showing a healthy pregnancy. She later suffered heavy bleeding and lost the baby after consuming a drink Banta had purchased for her. The Parker County Sheriff's Office laid out the allegation plainly:
"The victim reported that her boyfriend intentionally added 'Plan C,' (commonly known as the abortion drug) to her drink in order to force her to have an abortion without her knowledge or consent."
Investigators said Banta admitted on his phone to buying abortion drugs. Authorities allege he then remotely reset the device, deleting evidence, which led to the additional tampering charge.
The sheriff's office also noted a critical detail about the couple's dynamic before the alleged crime:
"The victim informed Banta of her desire to keep the baby."
Banta has been charged but not convicted. The capital murder charge under Texas law reflects the state's recognition of an unborn child as a victim in certain homicide statutes. If the allegations hold, this case represents the sharpest criminal consequence yet tied to the covert use of mail-order abortion pills.
The FDA's 2021 decision did not happen in a vacuum. It triggered a cascade of legal battles that have reached the highest levels of the federal judiciary. The Fifth Circuit ordered a nationwide halt to the mailing of mifepristone in a ruling that directly challenged the FDA's loosened framework, setting up a confrontation at the Supreme Court.
That confrontation arrived. The Supreme Court intervened to temporarily restore mifepristone access by mail and telehealth while the underlying legal questions played out. The justices' order kept the relaxed dispensing rules in place, but the litigation exposed deep fractures over whether the FDA had adequately considered safety risks when it dropped the in-person requirement.
The forced-abortion lawsuits add a dimension those judicial fights largely ignored. The appellate battles focused on the drug's safety for the woman who chooses to take it. These civil suits ask a different question: what about the woman who never chose at all?
Several of the lawsuits target the telehealth providers and mail-order pharmacies that filled the prescriptions. The plaintiffs allege those entities conducted little or no verification to confirm that the person ordering the pills was the same person who would ingest them. Under the old in-person dispensing rule, a clinician would hand the drug directly to the patient in a medical setting, creating at least a basic identity check.
The mail-order model eliminated that step. A telehealth consultation can be conducted by anyone with a phone and an internet connection. The pills arrive in a package. Nothing in the current regulatory framework requires the pharmacy to confirm that the recipient is the patient, or that the patient is the one who actually takes the medication.
The broader fight over abortion-pill regulations has played out alongside state-level court battles over abortion restrictions, but those cases center on a woman's right to choose the procedure. The forced-abortion claims flip the frame entirely. Here, the women wanted their babies. The pills were used against them.
The civil plaintiffs are pursuing damages on multiple theories, including assault, battery, negligence, and product liability. The claims against the men who allegedly administered the drugs are straightforward intentional-tort cases. The claims against telehealth prescribers and pharmacies raise harder questions about duty of care and foreseeability.
Courts will need to determine whether a prescriber or pharmacy that ships abortion pills by mail owes any duty to verify that the end user is the actual patient. If courts say yes, it could force changes to how telehealth abortion services operate nationwide. If courts say no, it leaves a gap that these lawsuits suggest bad actors have already learned to exploit.
The litigation also intersects with ongoing federal disputes over pharmaceutical industry accountability in the courts. Drug manufacturers and distributors have long argued that FDA approval and compliance with federal dispensing rules should shield them from state-law tort claims. Whether that defense holds when the FDA itself loosened the dispensing rules is an open question.
The FDA has not publicly addressed the forced-abortion lawsuits or indicated whether it is reviewing its 2021 decision in light of the allegations. The agency's adverse-event reporting system does not appear to have a clear mechanism for capturing cases where someone other than the patient administered the drug.
Investigators in the Banta case and in several of the civil suits have not said whether they sought records from the telehealth platforms or pharmacies involved. Authorities have not publicly confirmed how many of the online orders at issue were placed using the alleged victim's name versus the man's name, a detail that could determine whether the prescribing platforms had any reason to flag the transactions.
Prosecutors in jurisdictions where these incidents occurred will also need to determine whether existing criminal statutes adequately cover the covert administration of abortion drugs. Texas charged Banta with capital murder under its fetal-homicide law. Other states may lack equivalent statutes, leaving prosecutors to rely on assault or poisoning charges that may not capture the full gravity of ending a wanted pregnancy without the mother's knowledge.
The political fight over mifepristone has been framed almost entirely as a contest between access and restriction. Proponents of the FDA's 2021 change argued that requiring in-person dispensing created unnecessary barriers for women in rural areas or states with few abortion providers. Opponents argued the agency cut corners on safety review.
Neither side spent much time on the scenario these seven women describe: a regulatory change designed to empower women's choices being weaponized to destroy them. The lawsuits do not argue that mifepristone should be banned. They argue that the system built to deliver it has no safeguards against misuse by someone who is not the patient.
That distinction matters. It moves the conversation past the familiar pro-choice versus pro-life binary and into territory that should concern anyone who believes informed consent is the bedrock of medical care. A woman who never consented to taking a drug did not exercise a choice. She had one taken from her.
When regulators make it easier to get a powerful drug by mail with minimal verification, they own the foreseeable consequences. Seven lawsuits say those consequences have names, and those names belong to women who wanted to be mothers.
